Ravulizumab for treating paroxysmal nocturnal haemoglobinuria

  • Technology appraisal guidance
  • TA698
  • Published: 
Download guidance (PDF)

2 Information about ravulizumab

Marketing authorisation indication

2.1 Ravulizumab (Ultomiris, Alexion Pharmaceuticals) is indicated for 'the treatment of adult patients with paroxysmal nocturnal haemoglobinuria:

  • in patients with haemolysis with clinical symptom(s) indicative of high disease activity

  • in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.

Price

2.3 The list price is £4,533 per 300 mg/3 ml concentrate for solution for infusion vial; £16,621 per 1,100 mg/11 ml concentrate for solution for infusion vial (excluding VAT; company submission).

2.4 The company has a commercial arrangement. This makes ravulizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.